January 9, 2018

ASH 2017 Top 10 Abstracts

Hard hitters that caught our attention

Top10_650x450

The American Society of Hematology’s annual meeting provides an excellent opportunity to discover recent developments in the field. The staff of Cleveland Clinic Cancer Center’s Department of Hematology and Medical Oncology finds these 10 abstracts the most compelling, clinically relevant and potentially transformative to the practice:

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Late-Breaking Abstract No. 2

Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia — Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study

This study details the first randomized trial to show a clear progression-free and overall survival benefit to venetoclax (V) instead of bendamustine (B) when used in combination with rituximab (R) for relapsed CLL. Tolerability was favorable with only one event of clinical tumor lysis syndrome in each arm. High rates of minimal residual disease (MRD) negative state were achieved (83.5% in VR vs 23.1% with BR). These data are the best example of the superiority of targeted therapy for CLL when compared head-to-head against conventional chemotherapy.

Late-Breaking Abstract No. 4

Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan and Prednisone (D-VMP) Versus Bortezomib, Melphalan and Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible for Transplant (ALCYONE)

In a randomized phase 3 trial of 706 patients with multiple myeloma who were ineligible for high-dose chemotherapy and autologous transplantation, addition of daratumumab to VMP doubled the odds of achieving progression-free survival compared to VMP alone (72% vs 50% at 18 months). This increase in progression-free survival was attributed to more patients achieving deeper responses as evidenced by a higher rate of MRD negativity in the D-VMP arm.

Late-Breaking Abstract No. 6

A Randomized, Open-Label, Blinded Outcome Assessment Trial Evaluating the Efficacy and Safety of LMWH/Edoxaban Versus Dalteparin for Venous Thromboembolism Associated with Cancer: Hokusai VTE-Cancer Study

This study demonstrated that an oral FXa inhibitor, edoxaban, was noninferior to the low-molecular-weight heparin dalteparin in terms of efficacy and safety in cancer patients with thrombosis.

Abstract 2

Advertisement

Clinical Activity in a Phase 1 Study of Blu-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (AdvSM)

In this study, the authors use a KIT inhibitor in 30 heavily pretreated patients with systemic mastocytosis, and show that the majority of patients have reductions in serum tryptase levels, spleen size and D816 allele burden, along with regression in skin lesions.

Abstract 15

Phase 2, Multiple-Dose Study of Anti-FcRn Antibody, Rozanolixizumab (UCB7665), in Patients with Primary Immune Thrombocytopenia: Interim Analysis

This study is the first report of a new therapy, anti-FcRn antibodies, in patients with primary persistent or chronic immune thrombocytopenia (ITP). These antibodies prevent recycling of IgG immune complexes and reduce autoantibody levels. Clinically significant improvements in the platelet count occurred in 40 to 50 percent of generally extensively pretreated ITP patients.

Abstract 160

A Personalized Prediction Model to Risk-Stratify Patients with Myelodysplastic Syndromes (MDS)

In this study, Cleveland Clinic’s Aziz Nazha, MD, applies machine learning to 925 patients with myelodysplastic syndromes, incorporating both clinical and molecular factors. His system is able to predict survival at any time during a patient’s disease course and regardless of therapy more accurately than any other existing prognostic system. Learn more here.

Abstract 603

Achievement of Normal Circulating Factor VIII Activity Following Bmn 270 AAV5-FVIII Gene Transfer: Interim, Long-Term Efficacy and Safety Results from a Phase 1/2 Study in Patients with Severe Hemophilia A

This study demonstrated persistent and prolonged responses to Bmn 270, an adenovirus 5-FVIII gene therapy, with marked increases in the FVIII level, significant reductions in bleeding and minimal liver inflammation.

Abstract 625

Advertisement

Anticoagulation Therapy in Selected Cancer Patients at Risk of Recurrence of Venous Thromboembolism: Results of the Select-D Pilot Trial

This study demonstrated that the oral FXa inhibitor rivaroxaban was equivalent to dalteparin in terms of prevention of recurrent events in cancer patients with thrombosis. Rivaroxaban was also associated with an increased risk of clinically relevant non-major bleeding.

Abstract 725

Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study

In this study of 258 patients with mutated IDH1, 125 of whom had relapsed or refractory acute myeloid leukemia, the overall response rate was 30.4 percent, and response duration was 6.5 months. The drug was well tolerated. This is the first study to target this molecular mutation seen in approximately 6 to 10 percent of AML patients.

Abstract 740

Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-BCMA CAR T Cell Therapy

A multi-center phase I study of chimeric antigen receptor (CAR) T-cell therapy targeted towards B-cell maturation antigen (BCMA) showed overall response rate of 89 percent in 21 patients with heavily treated relapsed/refractory multiple myeloma. Other preclinical and clinical studies presented at the meeting also reported significant activity of BCMA CAR-T infusions in relapsed/refractory myeloma.

Related Articles

Doctors working on MGUS screening study
March 18, 2024
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Physician with patient
March 6, 2024
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Doctor measuring patient's waist size
February 26, 2024
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access

How antibody drug conjugates work
February 13, 2024
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

24-CNR-4545611-CQD-Podcast-967×544
February 1, 2024
Possibilities of CRISPR Technology (Podcast)

Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors

Disparities in multiple myeloma
January 25, 2024
Major Study Identifies Global Disparities in Drug Toxicity for Multiple Myeloma Treatment

Study of 401,576 patients reveals differences in cancer burdens as well as overall survival

Dr. Shilpa Gupta
December 27, 2023
A New Standard Emerges in Advanced Urothelial Carcinoma After Decades of First-Line Chemotherapy

Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy

Ad